Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Comparison between wharton's jelly and collagen natural hydrogels for human ovarian follicle transplantation as an artificial ovary

Tajbakhsh F., Ashtiani MK., Tavana S., Moini A., Fathi R.

Animal Study with a reported sample of 60 on Hair & Scalp, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
PLoS One (2025)
Reported sample size
60
Source database
Europe PMC
PMID
40811443
PMCID
PMC12352639
DOI
10.1371/journal.pone.0329690

Abstract (original English)

Artificial ovary (AO) is a bioengineered approach aimed at increasing fertility potential in certain cases, especially in women and prepubertal girls with a history of cancer. Some natural and synthetic materials can be used for ovary bioengineering. In the current study, we compared two natural hydrogel composites containing alginate (Alg): Wharton's Jelly (WJ/Alg) and Collagen (Col/Alg) as models for human AO. In total, six experimental groups were designed: WJ/Alg, Col/Alg, WJ/Alg+FSH, Col/Alg+FSH, WJ/Alg+EPO, and Col/Alg+EPO (n = 60). In each group, 40 isolated human ovarian follicles were seeded in 10 µl of the desired hydrogel and xenotransplanted into the right side of the peritoneum in ovariectomized NMRI mice for 1 week. FSH (7.5 IU) and Erythropoietin (EPO; 200 IU/kg as an angiogenic factor) were injected every other day. Histological and immunohistochemical assessments for Vimentin, CD45, and Ki67; Gene expression analysis for GDF9, Vegf, and CD45; and hormonal assays for estradiol and progesterone were performed. Histological staining showed that WJ/Alg can support follicle growth. In contrast, most of follicles in Col/Alg remained at the primordial stage. Although FSH injection helped granulosa cells differentiation, especially in the WJ/Alg group (507.6 ± 134.1 vs 1444 ± 493.6), and EPO injection increased blood vessels in both groups (p-value<0.0001), the follicl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
OvaryOvarian FollicleAnimalsHumansMiceProgesteroneCollagenFollicle Stimulating HormoneAlginatesErythropoietin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research